GeneDx Holdings Corp
For the period ended Dec 31, 2023. Filed Feb 23, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 23, 2024
WGS$54.83-16.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share and share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue | ||
| Diagnostic test revenue | $195,654 | $227,334 |
| Other revenue | 6,912 | 7,360 |
| Total revenue | 202,566 | 234,694 |
| Cost of services | 112,560 | 261,444 |
| Gross profit (loss) | 90,006 | (26,750) |
| Research and development | 58,266 | 86,203 |
| Selling and marketing | 60,956 | 122,075 |
| General and administrative | 133,755 | 216,167 |
| Impairment loss | 10,402 | 210,145 |
| Other operating expenses, net | 7,223 | 6,312 |
| Loss from operations | (180,596) | (667,652) |
| Non-operating income (expenses), net | ||
| Change in fair market value of warrant and earn-out contingent liabilities | 1,170 | 70,229 |
| Interest income (expense), net | 1,114 | (666) |
| Other income, net | 1,619 | 57 |
| Total non-operating income, net | 3,903 | 69,620 |
| Loss before income taxes | (176,693) | (598,032) |
| Income tax benefit | 926 | 49,052 |
| Net loss | $(175,767) | $(548,980) |
| Other comprehensive income, net of tax | ||
| Unrealized gain related to available for sale securities | 425 | — |
| Comprehensive loss | $(175,342) | $(548,980) |
| Weighted average shares outstanding of Class A common stock | 24,311,989 | 10,236,960 |
| Basic and diluted net loss per share, Class A common stock | $(7.23) | $(53.63) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.